Fig. 5 | Laboratory Investigation

Fig. 5

From: ARHGEF39 promotes tumor progression via activation of Rac1/P38 MAPK/ATF2 signaling and predicts poor prognosis in non-small cell lung cancer patients

Fig. 5

Expression and prognostic values of ARHGEF39 (A39) in NSCLC tissues. Western blotting detection (a) and the quantification (b) of A39 expression in 16 paired tumors (T) and peritumoral normal lung tissues (N); β-actin served as a loading control. c Representative figures showing negative or weak expression of A39 in normal bronchial epitheliums (a), alveoli (b); and positive cytoplasmic (c) or cytoplasmic/membranous (d) expression of A39 in squamous cell carcinomas; and positive cytoplasmic (e) or cytoplasmic/membranous (f) expression of A39 in adenocarcinomas. d Kaplan–Meier survival analysis revealed that the overall survival of patients with positive A39 expression was significantly shorter than those with negative A39 expression. e Results of online software survival prediction (KM Plotter). *P < 0.05; scale bar = 50 μm

Back to article page